Gajanana Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.70 M
- Paid Up Capital ₹ 0.70 M
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.26 M
- Revenue Growth 226.68%
- Profit Growth 40.49%
- Ebitda -3.00%
- Net Worth 6.08%
- Total Assets 10.98%
About Gajanana Biotech
Gajanana Biotech Private Limited (GBPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 September 2006 and has a history of 18 years and four months. Its registered office is in Medak, Telangana, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.70 M and a paid-up capital of Rs 0.70 M.
The company currently has active open charges totaling ₹2.26 M.
Rama Istamsetty and Yamuna Mukkera serve as directors at the Company.
Company Details
- Location
Medak, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U01403TG2006PTC051077
- Company No.
051077
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Sep 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Gajanana Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rama Istamsetty  | Director | Current | |
| Yamuna Mukkera | Director | 14-Jun-2024 | Current |
Financial Performance of Gajanana Biotech.
Gajanana Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 226.68% increase. The company also saw a substantial improvement in profitability, with a 40.49% increase in profit. The company's net worth moved up by a moderate rise of 6.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gajanana Biotech?
In 2023, Gajanana Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.26 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.23 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Dec 2020 | State Bank Of India | ₹0.96 M | Open |
| 12 Nov 2007 | State Bank Of India | ₹1.30 M | Open |
How Many Employees Work at Gajanana Biotech?
Unlock and access historical data on people associated with Gajanana Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gajanana Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gajanana Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
